

## Hammond, Michelle

---

**From:** Hammond, Michelle  
**Sent:** Wednesday, July 27, 2011 9:11 AM  
**To:** 'frick@gammacorp.com'  
**Subject:** Re: REQUEST FOR ADDITIONAL INFORMATION REGARDING CONTROL 575177

Re: North Hawaii Community Hospital

License No.: 53-29099-01  
Docket No.: 030-34081  
Control No.: 575177

Dear Mr. Frick:

This is in reference to your application dated April 28, 2011 requesting a renewal for Nuclear Regulatory Commission License 53-29099-01. In order to continue our review, we need the following information:

1. Please confirm the form of I-131 that the licensee will be using (ie, capsule, liquid, etc.) and if they will be injecting the I-131. Refer to ATT 9.4 of your license renewal application entitled "Other Equipment and Facilities". It states that liquid doses will be vented. However, there is no discussion of a bioassay program associated with the use of liquid forms of I-131.
2. If unsealed for of I-131 will be used, please confirm that you will implement a bioassay program (refer to page 8-54 in the link below).

<http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/sr1556v9r2-final.pdf#08-23>

We will continue our review upon receipt of this information. Please reply to my attention at the Region IV Office and refer to Mail Control No. 575177. Please respond to this e-mail by August 10, 2011. You may reply via e-mail as long as the response is attached in a PDF format or by fax to 817-860-8188.

Thanks,

*Michelle M. Hammond, MSc*  
*Health Physicist*  
*U.S. Nuclear Regulatory Commission, R-IV*  
*Division of Nuclear Materials Safety, Branch A*  
*office) 817-860-8127*  
*fax) 817-860-8188*  
[Michelle.Hammond@nrc.gov](mailto:Michelle.Hammond@nrc.gov)

## Hammond, Michelle

---

**From:** Ronald Frick [rfrick@gammacorp.com]  
**Sent:** Saturday, July 30, 2011 4:56 PM  
**To:** Hammond, Michelle  
**Subject:** Re: REQUEST FOR ADDITIONAL INFORMATION REGARDING CONTROL 575177

Ms. Hammond,

North Hawaii Community Hospital currently uses I-131 NaI in capsule form only, but may use it in liquid form in the future if necessary. I-131 NaI liquid is used for oral administration only. We have established and will maintain a bioassay program.

Please let me know if you need additional information.

Ronald Frick  
Gamma Corporation

>>> "Hammond, Michelle" <Michelle.Hammond@nrc.gov> 7/27/2011 4:10 AM >>>  
Re: North Hawaii Community Hospital

License No.: 53-29099-01  
Docket No.: 030-34081  
Control No.: 575177

Dear Mr. Frick:

This is in reference to your application dated April 28, 2011 requesting a renewal for Nuclear Regulatory Commission License 53-29099-01. In order to continue our review, we need the following information:

1. Please confirm the form of I-131 that the licensee will be using (ie, capsule, liquid, etc.) and if they will be injecting the I-131. Refer to ATT 9.4 of your license renewal application entitled "Other Equipment and Facilities". It states that liquid doses will be vented. However, there is no discussion of a bioassay program associated with the use of liquid forms of I-131.

2. If unsealed form of I-131 will be used, please confirm that you will implement a bioassay program (refer to page 8-54 in the link below).

<http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/sr1556v9r2-final.pdf#08-23>

We will continue our review upon receipt of this information. Please reply to my attention at the Region IV Office and refer to Mail Control No. 575177. Please respond to this e-mail by August 10, 2011. You may reply via e-mail as long as the response is attached in a PDF format or by fax to 817-860-8188.

Thanks,

Michelle M. Hammond, MSc  
Health Physicist  
U.S. Nuclear Regulatory Commission, R-IV Division of Nuclear Materials Safety, Branch A  
office) 817-860-8127  
fax) 817-860-8188